Literature DB >> 8630931

Childhood cancer in the United States. A geographical analysis of cases from the Pediatric Cooperative Clinical Trials groups.

J A Ross1, R K Severson, B H Pollock, L L Robison.   

Abstract

BACKGROUND: After injuries, cancer is the leading cause of death in children younger than 15 years in the United States. Despite dramatic increases in 5-year survival rates, more than 100,000 person-years of life are lost to childhood cancer each year. The exact proportion of pediatric cancer patients who receive care at centers that utilize up-to-date therapeutic protocols [such as those affiliated with the Childrens Cancer Group (CCG) or the Pediatric Oncology Group (POG)] remains unknown. The purpose of this study was to estimate the proportion and geographic distribution of childhood cancer patients in the United States who are seen at participating centers of the CCG and the POG.
METHODS: Patients included 21,026 incident pediatric cancer cases diagnosed from January 1, 1989 through December 31, 1991. Observed numbers of pediatric cancer cases were compared with expected numbers of cases calculated from incidence rates obtained from the Surveillance, Epidemiology, and End Results (SEER) Program and population counts obtained from the 1990 U.S. Census Bureau.
RESULTS: Approximately 94% of children younger than 15 years diagnosed with cancer are seen at an institution that is a member of either POG or CCG. Comparisons of the observed-to-expected numbers of incident cases in the age groups (birth-4 years, 5-9 years, 10-14 years, and 15-19 years) demonstrated ascertainment rates of 100, 93, 84, and 21%, respectively. In some regions within the United States the observed number of cases was significantly less than that expected number, including areas of Idaho, Oklahoma, and Virginia. In addition, there were areas in which the observed number of childhood cancer cases was substantially greater than that expected, including areas in California and Florida.
CONCLUSIONS: The membership of the cooperative clinical trials groups (the POG and CCG) ascertain and provide access to state-of-the-art treatment protocols for the vast majority of pediatric cancer patients in the country. For the younger age groups, the CCG and POG may represent a mechanism of case ascertainment that approximates a population-based series for the continental United States. Those areas that have large enough discrepancies in observed-to-expected numbers may warrant further investigation.

Entities:  

Mesh:

Year:  1996        PMID: 8630931     DOI: 10.1002/(SICI)1097-0142(19960101)77:1<201::AID-CNCR32>3.0.CO;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  30 in total

1.  A strategy to advance the evidence base in palliative medicine: formation of a palliative care research cooperative group.

Authors:  Amy P Abernethy; Noreen M Aziz; Ethan Basch; Janet Bull; Charles S Cleeland; David C Currow; Diane Fairclough; Laura Hanson; Joshua Hauser; Danielle Ko; Linda Lloyd; R Sean Morrison; Shirley Otis-Green; Steve Pantilat; Russell K Portenoy; Christine Ritchie; Graeme Rocker; Jane L Wheeler; S Yousuf Zafar; Jean S Kutner
Journal:  J Palliat Med       Date:  2010-11-24       Impact factor: 2.947

Review 2.  Pediatric surgical neuro-oncology: current best care practices and strategies.

Authors:  James T Rutka; John S Kuo
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

3.  Family history of cancer and non-malignant diseases and risk of childhood acute lymphoblastic leukemia: a Children's Oncology Group Study.

Authors:  Heather Zierhut; Martha S Linet; Leslie L Robison; Richard K Severson; Logan Spector
Journal:  Cancer Epidemiol       Date:  2011-10-21       Impact factor: 2.984

4.  Vitamin supplement use among children with Down's syndrome and risk of leukaemia: a Children's Oncology Group (COG) study.

Authors:  Cindy K Blair; Michelle Roesler; Yang Xie; Alan S Gamis; Andrew F Olshan; Nyla A Heerema; Leslie L Robison; Julie A Ross
Journal:  Paediatr Perinat Epidemiol       Date:  2008-05       Impact factor: 3.980

5.  Are experimental treatments for cancer in children superior to established treatments? Observational study of randomised controlled trials by the Children's Oncology Group.

Authors:  Ambuj Kumar; Heloisa Soares; Robert Wells; Mike Clarke; Iztok Hozo; Archie Bleyer; Gregory Reaman; Iain Chalmers; Benjamin Djulbegovic
Journal:  BMJ       Date:  2005-11-18

6.  Feasibility of neonatal dried blood spot retrieval amid evolving state policies (2009-2010): a Children's Oncology Group study.

Authors:  Amy M Linabery; Megan E Slater; Logan G Spector; Andrew F Olshan; Susan K Stork; Michelle A Roesler; Gregory H Reaman; Julie A Ross
Journal:  Paediatr Perinat Epidemiol       Date:  2011-08-10       Impact factor: 3.980

7.  Immune-related conditions and acute leukemia in children with Down syndrome: a Children's Oncology Group report.

Authors:  Amy M Linabery; Wenchao Li; Michelle A Roesler; Logan G Spector; Alan S Gamis; Andrew F Olshan; Nyla A Heerema; Julie A Ross
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-12-10       Impact factor: 4.254

8.  Maternal health conditions during pregnancy and acute leukemia in children with Down syndrome: A Children's Oncology Group study.

Authors:  Simona Ognjanovic; Susan Puumala; Logan G Spector; Franklin O Smith; Leslie L Robison; Andrew F Olshan; Julie A Ross
Journal:  Pediatr Blood Cancer       Date:  2009-05       Impact factor: 3.167

9.  Congenital abnormalities and acute leukemia among children with Down syndrome: a Children's Oncology Group study.

Authors:  Amy M Linabery; Cindy K Blair; Alan S Gamis; Andrew F Olshan; Nyla A Heerema; Julie A Ross
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09-30       Impact factor: 4.254

10.  Maternal vitamin and iron supplementation and risk of infant leukaemia: a report from the Children's Oncology Group.

Authors:  A M Linabery; S E Puumala; J M Hilden; S M Davies; N A Heerema; M A Roesler; J A Ross
Journal:  Br J Cancer       Date:  2010-10-26       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.